Potential new use of DXB’s drug in US$2.5 Billion market

Yesterday our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), announced an agreement with the Australian Centre for Accelerating Diabetes Innovation to commence a clinical trial on Diabetic Kidney Disease expected Q4 2022.

DXB Recruits First Patient, Gets FDA IND Approval

Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

Can This ASX Junior Surge Through the Pain Barrier?

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.